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Chapter 3 
 
Bone 
 
The use of dental implants in oral rehabilitation is becoming a standard method of care in 
dentistry. In the case of insufficient bone volume, a procedure for augmentation is needed. 
The ability to augment the alveolar ridge has gradually expanded the scope of implant 
dentistry. During the past 10 years, alveolar augmentation techniques have become 
established treatment modalities. Dahlin et al. reported an experimental study on rabbits 
involving the formation of new bone around titanium implants using the membrane 
technique [1]. In addition, various bone-grafting materials have been used for augmentation, 
including autologous grafts, freeze-dried bone grafts, hydroxyapatite and xenografts [2, 3]. 
Although the results of these investigations indicate that augmentation is clinically 
successful for various graft materials, it is questionable whether these materials, except for 
autologous bone, have adequate osteogenic potential and biomechanical properties [4, 5]. 
On the other hand, autologous bone, which currently remains the material of choice, is 
available for bone reconstructive procedures [6]. However, its use is limited due to donor 
site morbidity and limited amounts of graft material available for harvesting. 
To avoid these problems, we attempted to regenerate bone in a significant osseous defect 
with minimal invasiveness, and to provide a clinical alternative to the graft materials 
described above. The new technology that we developed is called “injectable 
tissue-engineered bone”, and involves the morphogenesis of new tissue using constructs 
formed from isolated cells with biocompatible scaffolds and growth factor, and was 
established based on tissue engineering concepts [7-9]. 
 
Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are frequently used for bone tissue engineering and 
increasingly applied in the clinic. Although engineering bone tissue using MSCs is feasible, the 
size of the regenerated bone is limited by nutrient transport. The grafted cells require an 
oxygen/nutrition supply to survive and early neovascularization is considered essential for 
successful bone tissue engineering. Development of an efficient neovascularization method to 
sustain the engineered implants is clinically important. The relationship between vascular 
endothelial factors (e.g. VEGF) and bone regeneration emphasizes the important role of 
vasculature not only for survival but also for the proper formation of tissue-engineered bone. 
In 1997, Asahara et al. characterized endothelial progenitor cells (EPCs) in human peripheral 
blood using magnetic beads selection [10]. Since EPCs can give rise to endothelial cells (ECs) 
and are known to facilitate the neovascularization of an implanted site, EPCs may be used to 
facilitate collateral vessel growth into ischemic tissues through delivery of antiangiogenic or 
proangiogenic agents. EPCs have been implanted into various ischemic tissue models, for 
example, ischemic hindlimbs and areas of myocardial infarction. Recently, EPCs have also 
been used to engineer blood vessels. Taken together, it is conceivable that supplementing 
osteogenic cells with ECs or EPCs may facilitate osteogenesis in tissue-engineered bone 
www.intechopen.com
Applied Tissue Engineering22
constructs. However, little is known about how EPCs may influence development of 
tissue-engineered bone. 
We investigated the potential of EPCs to facilitate neovascularization in implants and 
evaluated their influence on bone regeneration. The influence of EPC soluble factors on 
osteogenic differentiation of MSCs was tested by adding EPC culture supernatant to MSC 
culture medium. To evaluate the influence of EPCs on MSC osteogenesis, canine 
MSCs-derived osteogenic cells and EPCs were seeded independently onto collagen fiber 
mesh scaffolds and cotransplanted to nude mice subcutaneously. Results from co-implant 
experiments were compared to implanted cells absent of EPCs 12 weeks after implantation. 
Factors from the culture supernatant of EPCs did not influence MSC differentiation. 
Co-implanted EPCs increased neovascularization and the capillary score was 1.6-fold higher 
as compared to the MSC only group (P<0.05). Bone area was also greater in the MSC + EPC 
group (P<0.05) and the bone thickness was 1.3-fold greater in the MSC + EPC group than 
the MSC only group (P<0.05). These results suggest that soluble factors generated by EPCs 
may not facilitate the osteogenic differentiation of MSCs; however, newly formed 
vasculature may enhance regeneration of tissue-engineered bone (Fig. 9). 
 
 
Fig. 9. Soft X-ray radiographs of implants 12 weeks after implantation. A: MSC only group: 
MSC-derived osteogenic cells were seeded onto collagen, which was then wrapped with the 
same scaffold without cells. B: MSC and EPC group: MSC-derived osteogenic cells were 
seeded onto one scaffold, then covered with another scaffold seeded with EPCs (From 
Usami et al. 2006. Reprinted with permission).  
 
Tissue engineered bone ‘injectable bone’ 
We previously reported that tissue-engineered bone induces excellent bone regeneration 
and promotes bone formation in a grafted area treated with platelet-rich plasma (PRP), 
which contains various growth factors [8]. 
After a period of housing, 12 adult hybrid dogs with a mean age of 2 years were operated 
dMSCs were isolated from 10 ml samples of dog iliac bone marrow aspirates. Bone marrow 
cell isolation and expansion was performed according to previously published methods [11]. 
Briefly, basal medium (condition medium), low-glucose Dulbecco’s modified Eagles 
medium (DMEM) and growth supplements consisting of 50 ml of mesenchymal cell growth 
β β
β
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supplement, 10 ml of 200 mM L-glutamine and 0.5 ml of a penicillin–streptomycin mixture 
containing 25 U of penicillin and 25 µg of streptomycin. The three supplements used for 
inducing osteogenesis, dexamethasone (Dex), sodium β-glycerophosphate (β-GP) and 
L-ascorbic acid 2-phosphate (AsAP). The cells were incubated at 37°C in a humidified 
atmosphere containing 95% air and 5% CO2. dMSCs were replated at a density of 3.1 × 103 
cells/cm3 in 0.2 ml/cm2 condition medium. The implants were assessed by histological and 
histomorphometric analysis, 2, 4 and 8 weeks after implantation. The implants exhibited 
varying degrees of bone-implant contact (BIC). The BIC was 17%, 19% and 29% (control), 
20%, 22% and 25% (fibrin), 22%, 32% and 42% (dMSCs/fibrin) and 25%, 49% and 53% 
(dMSCs/PRP/fibrin) after 2, 4 and 8 weeks, respectively. This study suggests that 
tissue-engineered bone may be of sufficient quality for predictable enhancement of bone 
regeneration around dental implants when used simultaneous by with implant placement. 
Recent tissue engineering approaches have attempted to create new bone based on the use 
of MSCs seeded onto porous ceramic scaffolds with osteoconductive properties [12] (Fig. 10). 
These attempts have yielded sub-optimal results due to the slow resorption rate of 
hydroxyapatite-based ceramics. Also, these delivery substances do not exhibit good 
plasticity and the cellular implantation procedure is complicated by problems associated 
with the delivery vehicles because the block materials do not have plasticity. Isogai et al. 
reported that a combination of fibrin glue with delivery vehicle and cultured periosteal cells 
resulted in new bone formation at heterotopic sites in nude mice [13]. In numerous reports 
about materials, fibrin was found to have hemostatic effects and to promote wound healing. 
In a bone regeneration study using the rabbit tibia, Bosch et al. and Schwarz et al. reported 
that fibrin stimulated neovascularization of bone with accelerated healing and earlier new 
bone formation [14, 15]. Additionally, the use of fibrin as an osteoconductive material has 
been recommended [16]. Therefore, we used fibrin as a scaffold, which is one of the three 
key factors in the tissue engineering concept [9]. 
 
 
Fig. 10. Scanning electron microscopy photomicrograph of a cross-section of β-tricalcium 
phosphate. Bar = 500 µm (From Boo et al. 2002. Reprinted with permission).  
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Distraction osteogenesis using tissue engineered bone 
Distraction osteogenesis has become a widely accepted technique for reconstructing bone 
defects in the maxillofacial region. This technique provides autologous and predictable bone 
formation without grafting procedures but requires long-term treatment that includes latent, 
lengthening, and consolidation periods. The long treatment time results in a high rate of 
complications such as infection, pin loosening, and fracture. The recommended rate of 
gradual bone lengthening as described by Ilizarov is 1 mm per day [17]. A lower rate of 
distraction tends to result in bony union, whereas a higher rate of distraction may delay 
bone union or result in fibrous union. 
To promote bone formation and shorten the consolidation period, some attempts at 
applying hyperbaric oxygenation or electrical, ultrasonic, or chemical stimulation have been 
made [18]. Several recent studies have shown that injecting cells with osteogenic potential 
into distracted callus enhances its consolidation, but there have been few attempts at 
higher-rate distraction [19-22]. 
We previously reported on a tissue-engineered osteogenic material (TEOM) [23]. This 
material is an injectable gel of autologous MSCs, which are culture-expanded then induced 
to be osteogenic in character, and PRP activated with thrombin and calcium chloride. The 
injection of TEOM into the distraction gap has advantages. MSCs can be expanded and 
induced to osteoblastic lineage ex vivo. Moreover, both MSCs and PRP are autologous 
materials. 
Bilateral maxillary distraction was performed at a higher rate in rabbits to determine 
whether locally applied TEOM enhances bone regeneration (Fig. 11). The material was an 
injectable gel composed of autologous mesenchymal stem cells, which were cultured then 
induced to be osteogenic in character, and PRP. After a 5-day latency period, distraction 
devices were activated at a rate of 2.0 mm once daily for 4 days. Twelve rabbits were 
divided into 2 groups. At the end of distraction, the experimental group of rabbits received 
an injection of TEOM into the distracted tissue on one side, whereas, saline solution was 
injected into the distracted tissue on the contralateral side as the internal control. An 
additional control group received an injection of PRP or saline solution into the distracted 
tissue in the same way as the experimental group. The distraction regenerates were assessed 
by radiological and histomorphometric analyses. The radiodensity of the distraction gap 
injected with TEOM was significantly higher than that injected with PRP or saline solution 
at 2, 3, and 4 weeks postdistraction. The histomorphometric analysis also showed that both 
new bone zone and bony content in the distraction gap injected with TEOM were 
significantly increased when compared with PRP or saline solution. 
TEOM injection at the end of distraction promotes new bone formation following a higher 
rate of distraction. TEOM injection may be able to compensate for the insufficient distraction 
gap at a higher rate (Fig. 12). 
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Fig. 11. A: Schematic drawing of the maxilla and maxillary distraction. Red line, 
osteotomized line; yellow area, maxilla.  
 
 
Fig. 11. B: Distraction protocol and experimental design (From Kinoshita et al. 2008. 
Reprinted with permission). 
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Fig. 12. Histological view of the distracted maxilla, staining H-E. Experimental group A: 
TEOM-injected side; B: center of the distraction zone on the TEOM-injected side; C: saline 
solution-injected side; D: center of the distraction zone on the saline solution-injected side. 
Additional control group, E: PRP-injected side; F: center of the distraction zone on the 
PRP-injected side; G: saline solution-injected side; H: center of the distraction zone on the 
saline solution-injected side (From Kinoshita et al. 2008. Reprinted with permission).  
 
Bone regeneration using ‘periosteum’ 
The periosteum is comprised of two tissue layers: the outer fibroblast layer that provides 
attachment to soft tissue, and the inner cambial region that contains a pool of 
undifferentiated mesenchymal cells, which support bone formation [24]. Recently, studies 
have reported the existence of osteogenic progenitors, similar to MSCs, in the periosteum 
[25, 26]. Under the appropriate culture conditions, periosteal cells secrete extracellular 
matrix and form a membranous structure [27]. The periosteum can be easily harvested from 
the patient’s own oral cavity, where the resulting donor site wound is invisible. Owing to 
the above reasons, the periosteum offers a rich cell source for bone tissue engineering. 
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Our group has previously demonstrated bone regeneration using a cultured periosteum 
(CP) in a critical-sized rat calvaria bone defect [28] (Fig. 13). CP has also been shown to 
regenerate bone in a surgically created furcation bone defect using a canine model [27]. 
Considering the biocompatibility of CP and its capacity for alveolar bone regeneration, it 
should be useful to investigate the potential of CP for bone regeneration around an implant 
site. The purpose of this study was to investigate the potential of CP to regenerate bone to 
mitigate implant dehiscence defects.  
 
A 
B 
C 
 
Fig. 13. A–C: Photographs showing representative calvarial bone defect of athymic rats 3 
months after surgery. A: Animals with grafted fresh CP showed complete closure of 
calvarial defect. B: Animals, grafted with cryopreserved CP also showed complete closure of 
the defect, and there was no apparent difference between fresh and cryopreserved CP 
macroscopically. C: However, the bone defect of the control group without CP remained 
almost the same size as before grafting. Arrowheads indicate margin of original bone defect 
(From Mase et al. 2006. Reprinted with permission). 
 
Four healthy beagle dogs were used in this study. Implant dehiscence defects (4 × 4 × 3 mm) 
were surgically created at mandibular premolar sites where premolars had been extracted 3 
months back. Dental implants (3.75 mm in diameter and 7 mm in length) with machined 
surfaces were placed into the defect sites (14 implants in total). Each dehiscence defective 
implant was randomly assigned to one of the following two groups: (1) PRP gel without 
cells (control) or (2) a periosteum cultured on PRP gel (experimental). Dogs were killed 12 
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weeks after operation and nondecalcified histological sections were made for 
histomorphometric analyses including percent linear bone fill (LF) and bone-implant contact 
(BIC) (Fig. 14). Bone regeneration in the treatment group with a CP was significantly greater 
than that in the control group and was confirmed by LF analysis. LF values in the 
experimental and the control groups were 72.36 ± 3.14% and 37.03 ± 4.63%, respectively 
(P<0.05). The BIC values in both groups were not significantly different from each other. The 
BIC values in the experimental and the control groups were 40.76 ± 10.30% and 30.58 ± 
9.69%, respectively (P = 0.25) and were similar to native bone. 
 
T 
C 
P P 
(a) (b) (c)  
Fig. 14. Schematic drawing of the surgical procedures used in this study (P, Periosteum; C, 
Cortical bone; T, Trabecular bone). (a) Dog mandibular defect model (4 × 4 × 3 mm). (b) 
Implant placement. (c) Transplantation PRP gel (left) and cultured periosteum membrane on 
PRP gel (right) (From Mizuno et al. 2008). 
 
The consensus tissue engineering paradigm includes cells, scaffolds, and bioactive 
molecules. For periodontal therapy, there are several reports based on this tissue 
engineering paradigm that incorporate various polymers such as collagen and gelatin as a 
scaffold material [29-31]. However, natural biodegradable materials cannot eliminate the 
possible risk of infection and degraded products may interfere with the regeneration 
process. Instead of culturing cells on natural biodegradable scaffolds, we have been able to 
stimulate periosteal cells to form their own matrix and generate a cell-populated membrane 
in vitro [27]. This method creates a CP durable enough to be held by forceps, making it 
feasible to transplant CP without the need for a biodegradable support. Furthermore, the 
thickness of the CP is approximately 200 µm, which may be beneficial to cells, allowing 
oxygen and nutrients to diffuse into the transplanted tissue (Fig. 15).  
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Fig. 15. A, B: CP macroscopic and microscopic findings. Bovine periosteal cells were 
cultured for 4 weeks. A: The cells became a membranous structure with enough mechanical 
strength to handle with forceps. Cells can be obtained by a conventional explant culture of 
periosteal fragment. B: Phase-contrast photomicrograph showing the cultured CP. C: 
Photomicrograph showing hematoxylin and eosin staining of CP section. The CP is 
approximately 100–300 µm in thickness and consists of 20–30 cellular layers (From Mase et 
al. 2006. Reprinted with permission).  
 
A major disadvantage of using CP for clinical treatment might be the time period required 
for tissue culture. Four to 6 weeks is a typical time frame for obtaining CP with enough 
mechanical strength to be transplanted. Furthermore, the cultured period would likely differ 
for each patient and may be unpredictable at the beginning of culture. This uncertainty 
makes it difficult to formulate a treatment schedule in advance. To overcome this problem, 
we have investigated the potential of CP cryopreservation [28]. In this study, the optimal 
preincubation protocol for CP was investigated and it was found that CP could be 
successfully cryopreserved under specific conditions without loss of osteogenic potential. 
Cryopreservation of CP should increase the usefulness of these approaches in future clinical 
applications. This study demonstrated the feasibility of a CP to regenerate bone at implant 
dehiscence defect. 
 
Translational Research 
Translational research involves application of basic scientific discoveries into clinically 
germane findings and, simultaneously, the generation of scientific questions based on 
clinical observations. At first, as basic research we investigated tissue-engineered bone 
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regeneration using MSCs and PRP in a dog mandible model. We also confirmed the 
correlation between osseointegration in dental implants and the injectable bone. Bone 
defects made with a trephine bar were implanted with graft materials as follows: PRP, dog 
MSCs (dMSCs) and PRP, autologous particulate cancellous bone and marrow (PCBM), and 
control (defect only). Two months later, dental implants were installed. According to the 
histological and histomorphometric observations at 2 months after implants, the amount of 
BIC at the bone-implant interface was significantly different between the PRP, PCBM, 
dMSCs/PRP, native bone, and control groups. Significant differences were also found 
between the dMSCs/PRP, native bone, and control groups in bone density. These findings 
indicate that the use of a mixture of dMSCs/PRP will provide good results in implant 
treatment compared with that achieved by autologous PCBM. We then applied this 
injectable tissue-engineered bone to onlay plasty in the posterior maxilla or mandible in 
three human patients. Injectable tissue-engineered bone was grafted and, simultaneously, 
2-3 threaded titanium implants were inserted into the defect area. The results of this 
investigation indicated that injectable tissue-engineered bone used for the plasty area with 
simultaneous implant placement provided stable and predictable results in terms of implant 
success. We regenerated bone with minimal invasiveness and good plasticity, which could 
provide a clinical alternative to autologous bone grafts. This might be a good case of 
translational research from basic research to clinical application. 
 
Clinical application 
From these animal experiments, we adopted “injectable tissue-engineered bone” to 
regenerate bone in a significant osseous defect that was minimally invasive and had good 
plasticity, and to provide a clinical alternative to the graft materials mentioned above. One 
of the advantages of injectable tissue-engineered bone is the use of autologous cells for bone 
regeneration. Tissue engineering technology by autologous cell transplantation is one of the 
most promising therapeutic concepts being developed because it may solve problems, 
including donor site morbidity from autologous grafts, immunogenicity of allogenic grafts, 
and loosening of alloplastic implants. In this method, we use differentiated bone marrow 
derived stem cells (BMDSCs) as isolated cells for bone formation, and PRP as a growth 
factor and scaffold. In our hospital, we experienced many clinical cases using this method, 
such as maxillary sinus augmentation, periodontal treatment, and distraction [32-34]. We 
here report the procedures and results for these cases. 
 
Preparation of cells 
One and a half month before surgery, BMDSCs were isolated from the patient’s iliac crest 
bone marrow aspirates (20 ml) and cultured. The control medium contained the following: 
basal medium, low-glucose DMEM, 10% patient serum or 10% fetal bovine serum, and 
growth supplements (10 ml of 200 mM L-glutamine and 0.5 ml of a penicillin-streptomycin 
mixture containing 25 units of penicillin and 25 µg of streptomycin). Each patient could 
choose the type of serum (patient serum or fetal bovine serum) for cultivation of BMDSCs. 
For human serum preparation, human blood was isolated in a 200 ml collection bag under 
sterile conditions. Subsequently, the blood collected was centrifuged at 3500 rpm for 10 
minutes and the supernatant was collected. Three supplements for inducing 
osteogenesis—100 nM of dexamethasone, 10 mM of sodium β-GP, and 80 µg/ml of AsAP. 
Cells were incubated at 37°C in a humid atmosphere containing 95% air and 5% carbon 
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dioxide. Differentiated BMDSCs were trypsinized and used for implant placement. To verify 
the safety of cultured cells, the culture media were examined for contamination by bacteria, 
fungi, or mycoplasmas before transplantation. 
 
Preparation of PRP 
Preoperative hematology included complete blood count with platelet counts. PRP, 
extracted 1 day before surgery, was isolated in a 200 ml collection bag containing an 
anticoagulant, citrate, under sterile conditions in the Blood Transfusion Service of Nagoya 
University Hospital. Briefly, the blood collected was first centrifuged at 1500 rpm for 10 
minutes. Subsequently, the yellow plasma (containing the buffer coat that contained 
platelets and leukocytes) was removed. The second centrifugation was conducted at 3500 
rpm for 5 minutes to combine platelets with a single pellet. The plasma supernatant, which 
was platelet-poor plasma and contained a relatively small number of cells, was removed. 
The resulting pellet of platelets, the buffer coat/plasma fraction (PRP), was resuspended in 
remaining 20 ml of the plasma before use in the platelet gel. 
 
(c) (a) 
(d) 
(e) (b) 
(f)  
Fig. 16. Protocol of tissue engineered bone. (a) Harvest of bone marrow. (b) Cell culture and 
osteoinduction. (c) Collection of whole blood. (d) Centrifuge. (e) Platelet rich plasma. (f) 
Injection of tissue engineered bone (From Ueda et al. 2008). 
 
Preparation of injectable tissue-engineered bone 
PRP was stirred and stored at 22°C in a conventional shaker until used. Powdered human 
thrombin (500 units) was dissolved in 10% calcium chloride in a separate sterile cup. The 
PRP, BMDSCs (5.0 × 106 cells/ml), and air were aspirated into the first 2.5 ml sterile syringe. 
The thrombin-calcium chloride mixture (300 µl) was aspirated into the second 2.5 ml syringe. 
The two syringes were connected with a T connector, and the plungers of the syringe were 
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pushed and pulled alternatively, allowing air bubbles to flow back and forth between the 
two syringes. Within 5-30 seconds, the contents gained gel-like consistency because 
thrombin affected the polymerization of fibrin to produce an insoluble gel (Fig. 16). 
 
Application for maxillary sinus augmentation 
After tooth loss, alveolar augmentation of the extensively atrophied maxillary process may 
be required to restore the masticatory function of the patient by means of substitute teeth 
anchored on dental implants. In order to obtain adequate volume of bone enough to insert 
dental implants, elevation of the maxillary sinus floor has been carried out as a routine 
clinical procedure for more than 15 years [35-39]. Where the bone thickness between the 
maxillary sinus and the alveolar crest is less than 8 mm, sinus floor elevation without bone 
graft materials is insufficient. A bone graft-induced increase in the thickness of the alveolar 
sinus floor is necessary to support longer implants that are required [40, 41]. The success of 
the dental implants is to be evaluated over a long period of time. 
Sixteen sinus augmentations in 12 patients, partially or totally edentulous patients 44-60 
years of age (mean age: 54 years), were performed. All the patients had a conventional 
problem of denture retention due to severe posterior alveolar ridge atrophy; the average 
height of their residual sinus floor was <6 mm, for which sinus graft and dental implants 
would solve the problem. 
After routine oral and physical examinations, patients who did not desire to undergo any 
surgery for harvesting autologous bone were selected for injectable tissue-engineered bone 
grafting. They were healthy and free of any disease that might affect treatment outcomes 
(e.g., diabetes, immunosuppressive chemotherapy, and rheumatoid arthritis). Each patient 
was given detailed information about the intervention, including surgical techniques, types 
of graft material and dental implants, and the uncertainties of conducting a new 
bone-regenerative procedure. Informed consent in writing was requested of each patient. 
 
Surgical techniques 
Sinus augmentation was conducted under general anesthesia. The sinus grafting procedure 
followed Tatum’s classical description [35]. Briefly, the mucoperiosteal flap was elevated to 
create a trap door with a round hollow burr in the lateral wall of the maxillary sinus. After 
mobilization, the door was reflected inward. The space created by this procedure was filled 
with 1.8-5.4 g of injectable tissue-engineered bone to simultaneously place dental implants. 
The mucoperiosteal flap was repositioned and sutured in the usual manner. After surgery, 
patents received cephalosporins (300 mg/day) as antibiotics, and loxoprofen sodium (180 
mg/day) as analgesics for 3 days. 
 
Postoperative course 
The incidences of grafted bone resorption and implant loss after sinus augmentation with 
various bone substitutes have been recorded. The complete resorption of bone substitutes, 
especially autologous bone, was observed in 2.7% of patients [37]. However, this regenerated 
bone did not show resorption and remained in the sinus floor that had been elevated by 
injectable tissue-engineered bone. The mineralized tissue 2 years after operation increased by 
8.8 ± 1.6 mm, presumably due to the properties of tissue-engineered bone (Fig. 17). 
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Fig. 17. A: Preoperative macro view. B: Observation of second-stage surgery 6 months after 
the implant installation. The exposed thread was surrounded by newly formed bone and 
confirmed successful osseointegration. C: Last prosthesis observation by porcelain fused to a 
metal crown. These did not exceed 2 mm, and a healthy and firm peri-implant mucosa had 
been established. D: Panoramic radiograph, preoperative. E: Panoramic radiograph, 
postoperative. F: Panoramic radiograph, postoperative 1 year. G: Panoramic radiograph, 
postoperative 2 years. H: Panoramic radiograph, postoperative 3 years (From Ueda et al. 
2008. Reprinted with permission). 
 
For long periods of time, maxillary sinus floor augmentation has constituted a surgical 
procedure to gain bone mass required for placing dental implants. Further, there is also 
consensus that some threshold of osseous deficiency, vertical, horizontal, or both, exists at a 
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site where a sinus bone graft is required for successful implant treatment regardless of 
residual bone quality. If there is vertical bone less than 8 mm in height in the posterior 
maxilla, sinus floor elevation without bone graft materials is insufficient. A sinus graft 
should be strongly recommended to provide adequate support for the placement of dental 
implants [40, 41]. In these cases, the average residual bone height was 5.5 ± 1.6 mm (range: 
2-10 mm); therefore, we applied tissue-engineered bone as a graft material for the sinus graft. 
On the other hand, in our previous study [8, 23, 42-44], we found that the tissue-engineered 
bone was well-formed mature bone, and the bone-regenerating ability increased 
significantly compared to the nongrafted control of defect-only sites or PRP-only sites that 
had been reported not to function effectively for bone regeneration [45], confirming the 
radiological and histological data [8, 45]. In addition, we measured the values from a 
Vickers hardness test, which indicates mechanical properties for bone formation. The values 
of nongrafted control, PRP, autologous bone, and tissue-engineered bone were 8, 9, 13, and 
17, respectively, 2 weeks after operation [44]. Moreover, in our experiment we used rabbit 
maxillary sinus that has well-defined ostium similar to that of humans. The augmented 
height and bone volume showed peaks as early as 2 weeks in tissue-engineered bone sites; 
on the other hand, the volume of newly formed bone reached a peak value within 4 weeks 
in autologous bone sites at 2, 4, and 8 weeks of experimental time [42, 46]. Thus bone 
regeneration may indicate early bone formation and enhanced bone quality as the main 
advantages of BMDSCs, since our results were consistent with the report of our previous 
animal experiments [8, 23, 44]. 
This technique might be effective for maxillary sinus augmentation. This result also might 
be the effect of this grafted material, tissue-engineered bone by BMDSCs and PRP, and not 
the effect of sinus membrane elevation alone. The BMDSCs in the bone marrow are induced 
in cells with osteogenic capacity, and the MSCs in BMDSCs are considered more feasible for 
tissue engineering because the former proliferates faster due to a lower degree of 
differentiation. The PRP contains not only fibrinogen, which forms a fibrin network acting 
as a matrix, but also cytokinetic substances such as PDGF, TGF-β, IGF, and VEGF, which 
can stimulate MSCs to transform into osteoblasts [47]. The growth factors are believed to 
have an osseous regenerative effect on the MSCs and contribute to cellular proliferation, 
matrix formation, collagen synthesis, osteoid production, and other processes that accelerate 
tissue regeneration. However, further research will be required to examine the effect. 
Additionally, osseointegration is the most important condition for success in dental implant 
treatment. In clinical cases, implant loss occurs with no osseointegration because of infection, 
absorption and loss of bone volume. In our other study, we showed that the surface of implants 
attached to regenerated bone by tissue-engineered bone. Further, no infection was observed, and 
regenerated bone volume was not reduced 2 years after operation from the above-mentioned 
result. As a result, no implant loss was observed whatever because our procedures used 
autologous graft materials, autologous BMDSCs and PRP, in our cases (Fig. 18). 
 
 
www.intechopen.com
Chapter 3: Bone 35
β
(a) (b) 
(c) (d)  
Fig. 18. Protocol of tissue engineered bone for sinus lift. (a) Mixing osteoblasts and PRP. (b) 
Installation of dental implants. (c) Injection of tissue engineered bone. (d) Bone regeneration 
(From Ueda et al. 2005). 
 
Application for periodontal treatment 
Periodontal disease is an infectious disease that affects tooth-supporting tissues. Clinically, 
the color changes of the gingival, periodontal pocket formation, bleeding, clinical 
attachment loss of alveolar bone as detected on radiolucent disease is due to bacterial plaque 
in the periodontal pockets. The main aim of conventional periodontal therapy is to halt and 
possibly reverse the attachment loss resulting from the disease. To this end, initial therapy is 
focused on removal of bacterial plaque from teeth and periodontal pockets and prevention 
of supragingival plaque accumulation. Subgingival plaque can be removed by a nonsurgical 
form of therapy, such as scaling and root planing, or by surgical means. The efficacy of 
nonsurgical methods is well documented [48]. 
Several studies have confirmed the efficacy of mechanical subgingival plaque control in 
periodontal therapy, irrespective of the approach used [49]. Adequate supragingival plaque 
control by patients is required for successful periodontal treatment [50]. However, 
subgingival bacteria in deep pockets with compared anatomy, in infrabony pockets, and in 
areas of furcal involvement are sometimes difficult to remove with nonsurgical therapy. In 
those pockets, open access with surgical therapy may be indicated to clean the root surfaces. 
Even when inflammation has been eliminated and healthy periodontal tissue has been 
established after pathogenic microorganisms are removed from periodontal pockets, the 
anatomy of healed defects can be a problem, particularly in areas in which esthetics is 
critical and maintenance is difficult, such as in dentitions with gingival recession, infrabony 
defects, and furcations. 
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In the early 1980s, a series of experimental studies was conducted on a procedure to 
regenerate the lost attachment apparatus. A membrane was placed under the flap to prevent 
epithelial downgrowth and to create space for periodontal reformation [51]. The procedure, 
termed guided tissue regeneration (GTR), was introduced into the clinical setting by 
Gottlow et al. [52]. GTR therapy has been applied to furcation and infrabony sites under 
certain conditions, and its efficacy has been reported [53, 54]. However, it has been claimed 
that the new attachment between regenerated cementum obtained by GTR procedures and 
root dentin may not be as strong as the attachment between the original cementum and root 
dentin [55]. Because cementum formed following GTR therapy is apparently different from 
cementum formed during tooth development (a cellular cementum), the appropriateness of 
the term regeneration in the context of GTR therapy has been questioned [56]. Recently, 
some authors have started using the term true periodontal regeneration, which has been 
defined as “healing after periodontal treatment that results in the regain of lost supporting 
tissues, including a new cellular cementum attached to the underlying dentin surface, a new 
periodontal ligament with functionally oriented collagen fibers inserting into the new 
cementum, and new alveolar bone attached to the periodontal ligament [57].” Another 
technique, developed recently, is the application of enamel matrix derivatives to root 
surfaces. However, although these treatments have been reported to be effective for 
periodontal tissue regeneration, the indications for such treatments are rather limited and 
the amounts of regenerated tissue are not predictable. This indicates that further theoretical 
and technical developments are needed in the field of periodontal regenerative therapies 
before such therapy can be widely used in daily practice. 
In the previous cases, we used injectable tissue-engineered bone grafting to effectively 
regenerate bone for dental implant placement, and the result confirmed that tissue 
engineering can elicit as much bone regeneration as autologous bone grafts. So, we applied 
this method as periodontal regenerative therapy. 
 
Surgical techniques 
Immediately before surgery, the patient rinsed her mouth with 0.2% chlorhexidine solution 
for 90 seconds. The surgical area was anesthetized with lidocaine adrenaline 2%. Following 
pocket and releasing incisions, buccal and lingual full-thickness flaps were elevated and the 
epithelium was removed from the inside of the flaps. Granulation tissue residing in the 
defect area was carefully excised, and the root surface was scaled and planed. No bone 
recontouring was performed. Subsequently, MSCs-PRP gel was applied to the root surface 
and adjacent defect space. The flaps were replaced and closed with sutures. After 2 weeks, 
the sutures were removed. The patient was instructed to rinse three times daily with a 0.1% 
or 0.2% solution of chlorhexidine digluconate. Mechanical cleaning of the surgical site was 
not recommended during the first 4 postoperative weeks. Supportive care, including 
professional tooth cleaning, was performed every 2 months. 
 
Postoperative course 
By 1 year after this treatment, the pocket depth decreased from 5 mm to 1 mm. This clinical 
improvement should be predictable for teeth. Radiographic assessments revealed that the 
bone defect was indeed reduced in depth. But this may be a result of the short time allowed 
for a change in radiopacity; after a longer period, the postoperative progress would have 
become radiographically apparent. Whereas some regeneration may occur in humans 
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following a regenerative surgical approach, complete and predictable true regeneration is 
still difficult to attain. Based on recent clinical results, GTR therapy appears to have the most 
promising prospects for regeneration, although its clinical efficacy and predictability in 
periodontal defects have yet to be thoroughly tested in controlled clinical trials [57]. Also, 
when the GTR approach is used to treat periodontal defects, the risk of membrane exposure 
must be considered as a major complication [58-60]. The reported prevalence of membrane 
exposure is in the 70% to 80% range [61]. In such cases, adequate membrane fixation and 
soft tissue coverage can be difficult to perform. On the other hand, it is easier to apply 
injectable tissue-engineered bone, which is a formed gel, than to position a membrane 
around a defect, and since gingival recession and unesthetic outcomes occur when 
membranes become exposed, it seems logical to use tissue-engineered bone rather than a 
membrane. Also, the tissue-engineered bone assumes a firm, gel-like consistency and may 
have the ability not only to immobilize to implants in place but also to provide a seal around 
the tooth. In a preliminary animal study, tissue-engineered bone prevented downgrowth of 
the epithelium equally well as the GTR method. In addition, it has been claimed that the 
new attachment between regenerated cementum obtained from GTR procedures and root 
dentin may not be as strong or continuous as the attachment between the original cementum 
and root dentin [55]. On the other hand, in a periodontal tissue regeneration study using this 
treatment in dogs, MSCs played an important role in cementification, and the structure of 
regenerated cementum was similar to that of natural cementum on roots versus that 
regenerated using the GTR method. Therefore, injectable tissue-engineered bone treatment 
might be more useful than the GTR method for true periodontal and interdental papilla 
regeneration (Fig. 19). 
 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
 
Fig. 19. Protocol of tissue engineered bone for periodontal treatment. (a) Internal bevel 
incision. (b) Intersulcular incision. (c) Flap elevation. (d) Scaling and root planning. (e) 
Injection with tissue engineered bone. (f) Suture (From Yamada et al. 2006). 
 
Application to alveolar cleft defects 
The reconstruction of alveolar cleft defects is well established, with the most widely 
accepted approach being secondary alveolar cleft osteoplasty in the mixed dentition phase 
with autologous bone grafting [62, 63]. The source material for most bone grafts has been 
particulate marrow harvested from the anterior iliac crest, and this represents the standard 
material with which other materials from rib, mandible, calvarium, and tibia are compared 
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[62-64]. Donor site morbidity is an important factor in deciding the site for harvesting 
cancellous bone. Allogenic or xenogenic materials can eliminate this concern but not the risk 
of disease transmission. As another solution, the use of injectable tissue-engineered bone in 
bone augmentation procedures as a replacement for autologous bone grafts, offers 
predictable results with minimal donor-site morbidity [23, 65]. We considered that 
tissue-engineered bone is beneficial material for alveolar cleft osteoplasty, and applied this 
treatment. 
 
Surgical techniques 
Following a 3-cm-long mucosal incision at the level of the labiogingival junction, dissections 
were made in the ingrown scar tissue to reach the bony surface of the cleft walls. The tissue 
was then elevated in the subperiosteal plane to the levels of the anterior nasal spine 
anteriorly, the lateral piriform rim superiorly and to the alveolar ridges inferiorly, while 
taking care not to damage the unerupted teeth and the content of the incisive canal. The 
flaps of the nasal floor and the oral mucosa formed the ceiling and the floor of the cleft 
cavity, respectively. The ceiling, floor and front walls of the defect were supported with a 
0.1-mm-thick titanium-mesh plate. The thus-created pouch was filled with all the prepared 
TEOM through a syringe using a packer. Following release incisions in the periosteum and 
the scar tissue of the flaps and to allow them to cover the grafted area, the wound was 
closed without tension. 
 
Postoperative course 
Before this treatment, a 3-month-old female patient born with a congenital left unilateral 
cleft lip and alveolus underwent a cheiloplasty that resulted in no remaining oronasal fistula. 
At 9 years of age, computed tomograms (CTs) revealed that the left maxillary canine, lateral, 
and supernumerary incisors had formed half of their roots, and had closely surrounded the 
alveolar cleft bony defect which was 10 mm wide and 13 mm deep anteroposteriorly. The 
left central incisor was orthodontically overcorrected due to previous severe rotation and 
distal location (Fig. 20). 
The patient exhibited an uneventful postoperative course. The radiopacity of serial CTs 
slicing the middle level of the alveolar cleft in the grafted region increased gradually over 
time. Dome-shaped radiopaque images with 233 Hounsfield units (HU) faced one another, 
extended from the cleft bony walls inside the cavity after 3 months, and were fused together 
into an image with 324 HU after 6 months. The image increased in radiopacity to 447 HU in 
9 months, and at the bony bridge the lateral and supernumerary incisors horizontally 
migrated from their original positions in the respective major and minor segments. The 
incisive canal was reconstructed just medial to the bridge. The erupting canine and lateral 
incisor pushed the mesh plate vertically, and the mucosa covering the cleft consequently 
swelled and thinned. A mucosal cut was made in the crest of the alveolar ridge over these 
teeth, and the part with the plate overlying the teeth was removed under local anesthesia. 
The canine and the lateral incisor then erupted approximately at the same time (Fig. 21).  
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Fig. 20. The left unilateral cleft of the alveolus of our 9-year-old female patient. A: Intraoral 
view. B: Three-dimensional computed tomogram demonstrating the left maxillary canine and 
the alveolar bony defect (From Hibi et al. 2006. Reprinted with permission). 
 
A B 
 
Fig. 21. Intraoperative views: A: Exposed alveolar cleft defect. B: Cleft cavity grafted with 
the tissue-engineered osteogenic material. C: Graft covered with the titanium mesh plate 
(From Hibi et al. 2006. Reprinted with permission). 
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This material regenerated the bone in the alveolar cleft defect without donor-site morbidity 
resulting from the autologous bone graft. Grafted bone remodels new bone due to 
apposition following resorption, and Van der Meij et al. reported that 1-year postoperative 
volumetric rates were approximately 70% for secondary bone grafts before canine eruption 
[66]. Using their measuring method [67] at 9 months postoperatively the present case 
showed 79.1% regenerated bone. The same authors indicated that the eruption of the canine 
generally occurred 2 years after bone graft if the patient was 9 years old. High resorbability 
of the bone in the grafted region may result in the early eruption of canine (Fig. 22). 
 
A B 
C D 
 
Fig. 22. Serial computed tomograms slicing the middle level of the alveolar cleft.         
A: Preoperation. B: Three months postoperation. Dome-shaped radiopaque images facing 
together and extending from the cleft bony walls inside the cavity. C: Six months 
postoperation. Fused image in the cleft cavity. D: Nine months postoperation. The lateral 
and supernumerary incisors are approximated in the bony bridge lateral to the 
reconstructed incisive canal (From Hibi et al. 2006. Reprinted with permission). 
 
In the present case the canine coronally forced the mesh plate at 9 months postoperatively, 
which was earlier than expected. As the bone regenerated in the cleft defect, the ingrowing 
bone seemed to accompany the roots of not only the canine but also the lateral and 
supernumerary incisors, which consequently approximated and erupted. Bone regeneration 
with the injectable tissue-engineered may therefore have helped to induce teeth to 
reposition properly in the horizontal and vertical planes. Distraction of the transport bony 
segment has been attempted for closing alveolar defects. The defects are actually only 
reduced and not eliminated, and the teeth in the transport segment also were moved 
unintentionally according to the distraction. Some alteration in teeth positions may be 
beneficial, but others compromise crown morphology or require its recontouring. The bone 
transport in repair of the alveolar cleft therefore remains controversial (Fig. 23). Injectable 
tissue-engineered bone thus has a promising future. Its repeatability will also facilitate the 
sequential treatments of cleft palate patients. 
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Fig. 23. The canine and the lateral incisor erupting in the reconstructed alveolar ridge (From 
Hibi et al. 2006. Reprinted with permission). 
 
Taken together injectable tissue-engineered bone would provide a further option as a graft 
material for maxillary sinus floor augmentation, periodontal treatment, and distraction. The 
use of injectable tissue-engineered bone may well decrease healing time in days to come. 
Further, a tissue-engineered bone-induced increase in bone mass would potentially provide a 
great benefit to patients in cranio-maxillofacial and plastic surgery and to the bone 
reconstruction of other parts. Future research must address the long-term success rates of 
implants, the stability of tissue-engineered bone, and the application of the therapy to a less 
vascularized environment. Based on the present findings, future clinical trials are warranted. 
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